A Clinical Phase 2 Study of E6011 in Japanese Subjects with Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs Quetmolimab (Primary)
- Indications Cholangitis
- Focus Therapeutic Use
- Sponsors EA Pharma
- 03 Jan 2019 Status changed from active, no longer recruiting to discontinued.
- 10 Oct 2018 Planned End Date changed from 1 Feb 2022 to 1 Oct 2018.
- 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.